Anti-Tau (phospho S396) 抗体 [EPR2731] (ab109390)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR2731] to Tau (phospho S396)
- Suitable for: Dot blot, IHC-Fr, IHC-P, WB, IP
- Reacts with: Mouse, Rat, Human
Related conjugates and formulations
製品の概要
-
製品名
Anti-Tau (phospho S396) antibody [EPR2731]
Tau 一次抗体 製品一覧 -
製品の詳細
Rabbit monoclonal [EPR2731] to Tau (phospho S396) -
由来種
Rabbit -
特異性
The mouse and rat recommendation is based on the WB results. We do not guarantee IHC-P for mouse and rat.
The specificity of this antibody refers to P10636-8.
-
アプリケーション
適用あり: Dot blot, IHC-Fr, IHC-P, WB, IPmore details
適用なし: ICC/IF -
種交差性
交差種: Mouse, Rat, Human -
免疫原
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
(Peptide available asab226770) -
ポジティブ・コントロール
- WB: SH-SY5Y treated with alkaline phosphatase, Human and Mouse brain tissue lysate; IHC-P: human glioblastoma, human Alzheimer hippocampus, human, mouse and rat colon; IP- Human brain lysate; IHC-Fr: Mouse and Rat cerebrum tissue, Hu Alzheimer brain.
-
特記事項
Tau is a protein associated with several disease states, known collectively as tauopathies. The most well-known of these is Alzheimer’s disease (AD), were tau exhibiting excessive phosphorylation, aggregating to form neurofibrillary tangles. The epitope defined by phosphorylation of S396 in tau is strongly implicated in AD-associated tau pathology, providing a valuable target for the development of therapeutic antibodies to capture tau and prevent spreading of tau pathology.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. -
バッファー
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 40% Glycerol, 59% PBS, 0.05% BSA -
Concentration information loading...
-
精製度
Protein A purified -
ポリ/モノ
モノクローナル -
クローン名
EPR2731 -
アイソタイプ
IgG -
研究分野
関連製品
-
Alternative Versions
-
Compatible Secondaries
-
Immunizing Peptide (Blocking)
-
Isotype control
-
Related Products
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab109390の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
Dot blot |
1/1000.
|
|
IHC-Fr | (2) |
1/100.
Heat mediated antigen retrieval using sodium citrate buffer (10mM citrate pH 6.0 + 0.05% Tween-20) |
IHC-P | (5) |
1/4000. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
The mouse and rat recommendation is based on the WB results. We do not guarantee IHC-P for mouse and rat. |
WB | (3) |
1/10000 - 1/50000. Predicted molecular weight: 79 kDa.Can be blocked with Human Tau (phospho S396) peptide (ab226770).
For unpurified, use 1/10000 - 1/50000. |
IP |
1/10 - 1/100.
|
特記事項 |
---|
Dot blot
1/1000. |
IHC-Fr
1/100. Heat mediated antigen retrieval using sodium citrate buffer (10mM citrate pH 6.0 + 0.05% Tween-20) |
IHC-P
1/4000. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. The mouse and rat recommendation is based on the WB results. We do not guarantee IHC-P for mouse and rat. |
WB
1/10000 - 1/50000. Predicted molecular weight: 79 kDa.Can be blocked with Human Tau (phospho S396) peptide (ab226770). For unpurified, use 1/10000 - 1/50000. |
IP
1/10 - 1/100. |
ターゲット情報
-
機能
Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization. -
組織特異性
Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system. -
関連疾患
Note=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU).
Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.
Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.
Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.
Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104, 260540]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613. -
配列類似性
Contains 4 Tau/MAP repeats. -
発生段階
Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain. -
ドメイン
The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats. -
翻訳後修飾
Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK: CDK1, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis.
Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.
Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD. -
細胞内局在
Cytoplasm > cytosol. Cell membrane. Cytoplasm > cytoskeleton. Cell projection > axon. Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components. - Information by UniProt
-
参照データベース
- Entrez Gene: 4137 Human
- Entrez Gene: 17762 Mouse
- Entrez Gene: 29477 Rat
- Omim: 157140 Human
- SwissProt: P10636 Human
- SwissProt: P10637 Mouse
- SwissProt: P19332 Rat
- Unigene: 101174 Human
see all -
製品の状態
There are 9 isoforms produced by alternative splicing. -
別名
- AI413597 antibody
- AW045860 antibody
- DDPAC antibody
see all
画像
-
Immunohistochemistry analysis of frozen mouse cerebrum tissue sections labeling Tau (phospho S396) with ab109390 at 1/100 (1 μg/mL). ab150077 AlexaFluor®488 Goat anti-Rabbit at 1/1000 (2 μg/mL) was used as the secondary antibody. Sections were fixed with 4% PFA and permeabilised with 0.2% Triton X-100. DAPI (blue) was used as nuclear counterstain. Antigen retrieval was heat mediated using sodium citrate buffer (10mM citrate pH 6.0 + 0.05% Tween-20).
Cytoplasmic staining on mouse cerebrum, the signal decreased after phosphatase treatment at 37℃ for 2h.
-
All lanes : Anti-Tau (phospho S396) antibody [EPR2731] (ab109390) at 1/1000 dilution
Lane 1 : Human brain lysate
Lane 2 : Human brain lysates and the membrane was incubated with alkaline phosphatase
Lane 3 : Human brain lysates and the membrane was incubated with lambda phosphatase
Lysates/proteins at 15 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution
Predicted band size: 79 kDa
Observed band size: 50-79 kDa why is the actual band size different from the predicted?
Exposure time: 100 secondsBlocking/Diluting buffer and concentration 5% NFDM/TBST
Tau assembles into oligomers as described in PMID: 28382304, 32692785 and 30120733.
-
All lanes : Anti-Tau (phospho S396) antibody [EPR2731] (ab109390) at 1/1000 dilution
Lane 1 : Mouse brain lysate
Lane 2 : Mouse brain lysates and the membrane was incubated with alkaline phosphatase
Lane 3 : Mouse brain lysates and the membrane was incubated with lambda phosphatase
Lysates/proteins at 15 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution
Predicted band size: 79 kDa
Observed band size: 50-79 kDa why is the actual band size different from the predicted?
Exposure time: 10 secondsDiluting/Diluting buffer and concentration 5% NFDM/TBST
Tau assembles into oligomers as described in PMID: 28382304, 32692785 and 30120733..
-
All lanes : Anti-Tau (phospho S396) antibody [EPR2731] (ab109390) at 1/20000 dilution (purified)
Lane 1 : Untreated SH-SY5Y
Lane 2 : SH-SY5Y treated with alkaline phosphatase
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : HRP goat ant-rabbit (H+L) at 1/1000 dilution
Predicted band size: 79 kDa
Observed band size: 50-70 kDa why is the actual band size different from the predicted?Blocking buffer: 5% NFDM/TBST
Dilution buffer: 5% NFDM/TBST
-
IHC image of Tau (phospho S396) staining in a section of frozen normal human Alzheimer brain performed on a Leica BONDTM system using the standard protocol. The section was fixed in 10% paraformaldehyde (10 min) prior to staining. The section was incubated with ab109390, 1/1000 dilution, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. The inset secondary-only control image is taken from an identical assay without primary antibody.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Tau (phospho S396) antibody [EPR2731] (ab109390)
Immunohistochemical staining of paraffin embedded human glioblastoma with purified ab109390 at a dilution of 1/4000. A pre-diluted HRP polymer for rabbit/mouse IgG was used as the secondary antibody and the sample was counter-stained wirh hematoxylin. Antigen retrieval was perfomed using Tris-EDTA buffer, pH 9.0. PBS was used instead of the primary antibody as the negative control, and is shown in the inset.
-
ab109390 at 1/20 immunoprecipitating Tau (phospho S396) in Human brain lysate.
Lane 1 (input): Human brain lysate (10µg)
Lane 2 (+): ab109390 + Human brain lysate.
Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab109390 in Human brain lysate.
For western blotting, ab109390 at 1/1000 dilution followed by VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/5000 dilution.
Diluting / Blocking buffer and concentration: 5% NFDM/TBST.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Tau (phospho S396) antibody [EPR2731] (ab109390)
Immunohistochemistry analysis of paraffin-embedded human colon tissue sections labelling Tau (phospho S396) with ab109390 at 1/4000 dilution (0.026 μg/mL). The section was incubated with ab109390 for 30 mins at room temperature. Rabbit specific IHC polymer detection kit HRP/DAB (ab209101) was used as the secondary antibody. Sections were counterstained with Hematoxylin. Antigen retrieval was heat mediated using Bond™ Epitope Retrieval Solution 2 (pH 9.0) for 20 minutes.
Positive staining on ganglions of human colon without alkaline phosphatase treatment (image A); No signal was detected when tissues were treated with alkaline phosphatase (image B).The immunostaining was performed on a Leica Biosystems BOND® RX instrument. -
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Tau (phospho S396) antibody [EPR2731] (ab109390)Image courtesy of Carl Hobbs, Kings College London, U.K.
IHC image of Tau (phospho S396) staining in human Alzheimer hippocampus formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with citrate buffer. The section was then incubated with unpurified ab109390 at 1/1000 dilution for 2 hoursat 21ºC. A biotin conjugated goat-anti-rabbit antibody was used as a secondary at 1/250. The section shows clear neurofibrillary tangles in a subset of neurons.
-
Dot blot analysis of Tau (phospho S396) phospho peptide (Lane 1) and Tau non-phospho peptide (Lane 2) labeling Tau (phospho S396) with ab109390 at a dilution of 1/1000. ab97051 (Peroxidase conjugated goat anti-rabbit IgG) (H+L) at 1/100 000 was used as the secondary antibody.
Blocking and diluting buffer: 5% NFDM/TBST.
Exposure time: 3 minutes.
プロトコール
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (127)
ab109390 は 127 報の論文で使用されています。
- Rivas-Santisteban R et al. The Expression of Cellular Prion Protein, PrPC, Favors pTau Propagation and Blocks NMDAR Signaling in Primary Cortical Neurons. Cells 12:N/A (2023). PubMed: 36672218
- Son M et al. Abnormal Hyperphosphorylation of Tau in Canine Immune-mediated Meningoencephalitis. In Vivo 37:1065-1076 (2023). PubMed: 37103078
- Hernandez CM et al. Transfusion with Blood Plasma from Young Mice Affects rTg4510 Transgenic Tau Mice Modeling of Alzheimer's Disease. Brain Sci 13:N/A (2023). PubMed: 37371321
- Lv J et al. NPLC0393 from Gynostemma pentaphyllum ameliorates Alzheimer's disease-like pathology in mice by targeting protein phosphatase magnesium-dependent 1A phosphatase. Phytother Res 37:4771-4790 (2023). PubMed: 37434441
- Li S et al. Inhibition of AGEs-RAGE-PP2A Axis Alleviates Cognitive Impairment after Chronic Heart Failure. Cell Mol Biol (Noisy-le-grand) 69:179-185 (2023). PubMed: 37571882